The Patent Finder

COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY

Nitto Denko Corporation

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 6 of these applications claim priority to application 61/494,710, filed Jun 8, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 10,195,145Method for Treating Fibrosis Using Sirna and a Retinoid-Lipid Drug Carrier
In force
 · Medium confidence
UsedRemaining
Nitto Denko CorporationIn forceMedium confidence
US 9,408,864Composition for Regenerating Normal Tissue from Fibrotic Tissue
In force
 · High confidence
Nitto Denko CorporationIn forceHigh confidence
US 9,011,903Cationic Lipids for Therapeutic Agent Delivery Formulations
In force
 · High confidence
Nitto Denko CorporationIn forceHigh confidence
US 9,242,001Cationic Lipids for Therapeutic Agent Delivery Formulations
In force
 · High confidence
Nitto Denko CorporationIn forceHigh confidence
US 9,393,315COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY
In force
 · High confidence
Nitto Denko CorporationIn forceHigh confidence
US 9,456,984Method for Treating Fibrosis Using Sirna and a Retinoid-Lipid Drug Carrier
In force
 · High confidence
Nitto Denko CorporationIn forceHigh confidence
US 9,963,424Cationic Lipids for Therapeutic Agent Delivery Formulations
In force
 · High confidence
Nitto Denko CorporationIn forceHigh confidence
US 10,000,447COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY
In force
 · High confidence
Nitto Denko CorporationIn forceHigh confidence
US 10,100,004COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY
In force
 · High confidence
Nitto Denko CorporationIn forceHigh confidence
US 10,196,637Retinoid-Lipid Drug Carrier
In force
 · Medium confidence
Nitto Denko CorporationIn forceMedium confidence
25 more records in this group · Pro
10 of 35 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 35, including 9 expired.
Upgrade to Pro
13 of these are in force and held by Nitto Denko Corporation.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited